论文部分内容阅读
Backgroud A systematic review was undertaken to evaluate the clinical effectiveness of roflumilast, a selective phosphodiesterase 4 inhibitor, on pulmonary function, exacerbation rate, quality of life, and adverse events in stable chronic obstructive pulmonary disease(COPD).